Pfizer (PFE) Payables (2009 - 2026)
Pfizer (PFE) posted quarterly Payables of $4.5 billion for Q1 2026, down 14.01% year-over-year from $5.2 billion in Q1 2025, and down 41.37% quarter-over-quarter from $7.7 billion in Q4 2025.
Pfizer (PFE) Payables (2009 - 2026) Analysis & Trends
Pfizer (PFE) has reported Payables for 18 consecutive years, with $4.5 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Payables fell 14.01% year-over-year to $4.5 billion; the TTM figure through Mar 2026 stood at $4.5 billion (down 14.01% YoY), while the FY2025 annual figure was $7.7 billion, down 4.77% from the prior year.
- Payables retreated to $4.5 billion in Q1 2026 per PFE's latest filing, from $7.7 billion in the prior quarter.
- Across five years, Payables topped out at $9.1 billion in Q4 2022 and bottomed at $4.5 billion in Q1 2026.
- Historically, Payables has averaged $6.9 billion across 5 years, with a median of $7.5 billion in 2024.
- Annual changes were most pronounced in 2022 — Payables jumped 35.48% — and 2026, when it slipped 14.01%.
- Pfizer's Payables stood at $9.1 billion in 2022, then retreated by 0.33% to $9.1 billion in 2023, then fell by 11.14% to $8.1 billion in 2024, then retreated by 4.77% to $7.7 billion in 2025, then plunged by 41.37% to $4.5 billion in 2026.
- Business Quant data shows PFE's Payables at $4.5 billion in Q1 2026, $7.7 billion in Q4 2025, and $5.0 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | 20.92 Bn |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | 33.30 Bn |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | 5.96 Bn |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | 4.26 Bn |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | 22.89 Bn |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | 2.87 Bn |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | 674.00 Mn |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 7.03 Bn |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | -25.00 Bn |
| 10 | Sanofi | 54.20 Bn | 46.82 Bn | 10.79 Bn | 8.31 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 28, 2026 | 7.03 Bn |
| Mar 29, 2026 | 4.51 Bn |
| Dec 31, 2025 | 7.69 Bn |
| Sep 28, 2025 | 5.02 Bn |
| Jun 29, 2025 | 7.61 Bn |
| Mar 30, 2025 | 5.24 Bn |
| Dec 31, 2024 | 8.07 Bn |
| Sep 29, 2024 | 5.31 Bn |
| Jun 30, 2024 | 7.49 Bn |
| Mar 31, 2024 | 5.59 Bn |
| Dec 31, 2023 | 9.08 Bn |
| Jul 2, 2023 | 8.40 Bn |
| Apr 2, 2023 | 6.12 Bn |
| Dec 31, 2022 | 9.11 Bn |
| Jul 3, 2022 | 8.45 Bn |
| Apr 3, 2022 | 5.51 Bn |
| Dec 31, 2021 | 7.83 Bn |
| Oct 3, 2021 | 6.89 Bn |
| Jul 4, 2021 | 6.51 Bn |
| Apr 4, 2021 | 4.06 Bn |